**Supplementary table 6: Adverse reaction recorded, at initial treatment and 3-month follow-up.**

|  |  |  |
| --- | --- | --- |
| This table shows the percentage of all paediatric patients for whom an adverse reaction was recorded by type of reaction between 1 March 2015 and 29 February 2016. **Adverse reactions, % (n)** | **Initial treatment**  **(n=278)** | **3-month follow-up**  **(n=121)** |
| Adverse reaction recorded  Yes= | 1% (4) | 5% (6) |
| Abdominal pain | 0% (0) | 0% (0) |
| Alopecia | 0% (0) | 0% (0) |
| Angioedema of upper airway | 0% (0) | 0% (0) |
| Arthralgia | 0% (0) | 0% (0) |
| Blood abnormality | 0% (0) | 0.8% (1) |
| Bronchospasm (cough/wheeze/dyspnoea) | 0% (0) | 0% (0) |
| Cardiac failure | 0% (0) | 0% (0) |
| Chest pain | 0% (0) | 0% (0) |
| Chills | 0% (0) | 0% (0) |
| Confirmed demyelination | 0% (0) | 0% (0) |
| Death | 0% (0) | 0% (0) |
| Difficulty breathing | 0% (0) | 0.8% (1) |
| Dizziness | 0% (0) | 0% (0) |
| Fatigue | 0% (0) | 0% (0) |
| Fever | 0% (0) | 2% (2) |
| Flushing | 0% (0) | 0% (0) |
| Headache | 0% (0) | 0% (0) |
| Hypotension | 0% (0) | 0% (0) |
| Infection | 0% (0) | 0% (0) |
| Injection site reaction | 0% (0) | 0% (0) |
| Itching | 0% (0) | 0% (0) |
| Limb weakness | 0% (0) | 0% (0) |
| Malignancy | 0% (0) | 0% (0) |
| Nausea | 0% (0) | 0% (0) |
| Panic attacks | 0% (0) | 0% (0) |
| Rash | 0% (0) | 2% (2) |
| Serum sickness-like reaction | 0% (0) | 0% (0) |
| Urticaria | 0% (0) | 0% (0) |
| Other | 1% (4) | 2% (2) |